Nktx stock forecast.

Analyst projections state that NKTX is forecast to be at a low of $10.00 and a high of $25.00. In order for the stock price to hit the forecast high, the stock would need to plunge -972.96% from its current level, while the stock would need to crash -329.18% from its current level to reach the projected low. Nkarta Inc (NKTX) estimates and ...

Nktx stock forecast. Things To Know About Nktx stock forecast.

Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...Nkarta, Inc. Common Stock (NKTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.When planning outdoor activities or making travel arrangements, having access to accurate weather forecasts is crucial. One commonly used tool is the 7 day weather forecast, which provides an outlook for the upcoming week.Dec 1, 2023 · The Nkarta Inc. stock price gained 1.16% on the last trading day (Friday, 24th Nov 2023), rising from $2.59 to $2.62. During the last trading day the stock fluctuated 3.53% from a day low at $2.55 to a day high of $2.64. The price has risen in 6 of the last 10 days and is up by 27.8% over the past 2 weeks. Volume fell on the last day by -163 ...

When Nkarta last reported its balance sheet in June 2022, it had zero debt and cash worth US$413m. Looking at the last year, the company burnt through US$78m. That means it had a cash runway of ...

Get Opthea Ltd (OPT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC ... NKTX. Nkarta Inc. 2.72, +0.08, +3.03%. GALT. Galectin ...

$3.33. BLNK 3.42%. Nkarta Inc. $2.72. NKTX 3.03%. Aclaris Therapeutics Inc. $0.90. ACRS 3.30%. Innate Pharma SA. $2.44. IPHA 1.67%. Ventyx Biosciences Inc.Of the 101 institutional investors that purchased Nkarta stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Deep Track Capital LP ($2.11M), State Street Corp ($2.05M), Wasatch Advisors LP ($1.98M), Braidwell LP ($1.53M), Price T Rowe Associates Inc. MD ($1.52M), Tang …Nkarta Inc Ordinary Shares NKTX Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...We would like to show you a description here but the site won’t allow us.Volume 525.26K. Average Volume (3M) 2.57M. Market Cap. $128.32M. Enterprise Value -$61.93M. Total Cash (Recent Filing) $280.75M. Total Debt (Recent Filing) $90.50M. Price to Earnings (P/E) -1.0. Beta 0.73.

Dec 1, 2023 · Valuation metrics show that Nkarta, Inc. may be fairly valued. Its Value Score of C indicates it would be a neutral pick for value investors. The financial health and growth prospects of NKTX ...

Find real-time GSK - GSK plc stock quotes, company profile, news and forecasts from CNN Business.

2.77%. $114.38M. NVAX | Complete Novavax Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Find the latest Nuveen California AMT-Free Quality Municipal Income Fund (NKX) stock quote, history, news and other vital information to help you with your stock trading and investing.Heading out for an outdoor adventure? Whether you’re planning a picnic, a hiking trip, or a beach day, one essential tool you need in your arsenal is a detailed weather 10 day forecast.Find market predictions, NKTX financials and market news. TradingView India. View live Nkarta, Inc. chart to track its stock's price action. Find market predictions, NKTX financials and market news. ... Market closed Market closed. No trades. See on Supercharts. Overview . News Ideas Financials Technicals Forecast . NKTX chart. Today −0.61% ...NKTX | Oversold Healthcare Play | LONG Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific p Nkarta, Inc., a a clinical-stage biopharmaceutical ...Find real-time EDIT - Editas Medicine Inc stock quotes, company profile, news and forecasts from CNN Business.Vertex Energy Inc () Stock Market info Recommendations: Buy or sell Vertex Energy stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Vertex Energy share forecasts, stock quote and buy / sell signals below.According to present data Vertex Energy's VTNR shares and potentially its market environment have …

Dec 1, 2023 · Analyst Forecast According to 6 analysts, the average rating for NKTX stock is "Strong Buy." The 12-month stock price forecast is $13.0, which is an increase of 377.94% from the latest price. Cava Group made its public market debut on the New York Stock Exchange under the ticker “CAVA.”. The company sold 14.4 million shares, raising nearly $318 million and valuing the restaurant ...Oct 2, 2023 · Since the start of the year, NKTX lost 77% of its equity value. However, in sharp contrast to the market performance, analysts rate NKTX a unanimous strong buy. Their average price target lands at ... Nov 29, 2023 · Nkarta (NKTX) is a clinical-stage biopharmaceutical company that develops and commercializes cell therapies for cancer treatment. The company's co-lead product candidates are NKX101 and NKX019, which are in phase I trials for various B cell malignancies. Analysts have a consensus rating of Buy and a price target of $15.67, up 671.8% from its current price of $2.03. Find the latest Quoin Pharmaceuticals, Ltd. (QNRX) stock quote, history, news and other vital information to help you with your stock trading and investing.

14,305.03 +78.81(+0.55%) Russell 2000 1,862.64 +53.62(+2.96%) Crude Oil 74.38 -1.58(-2.08%) Gold 2,091.70 +34.50(+1.68%) Advertisement Nkarta, Inc. (NKTX) NasdaqGS - NasdaqGS Real Time Price....

The analyst firm set a price target for $9.00 expecting NKTX to rise to within 12 months (a possible 230.88% upside). 17 analyst firms have reported ratings in the last year. Q We would like to show you a description here but the site won’t allow us.News Nkarta Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-2.50 Market Cap $128.57 M Shares Outstanding 49.07 M …Nkarta (NKTX) Company Description: Nkarta Inc is a bio-pharmaceutical company focused on the discovery, development and commercialization of engineered, allogeneic, and off-the-shelf cell ...The Latest Analyst Ratings for Nkarta. Nkarta has an average price target of $12.0 with a high of $15.00 and a low of $9.00. 5 analysts have provided ratings for nkarta over the past 3 months. According to 5 analyst offering 12-month price targets in the last 3 months, the stock has been rated bullish. Benzinga · 11/16 10:00.Nkarta Stock (NASDAQ: NKTX) stock price, news, charts, stock research, profile. ... Positive Outlook for Nkarta's Stocks: Key Developments and Future Expectations in NK Cell Therapy.On June 22, six executives sold a total of 4,033 shares of Nkarta, including CEO Paul Hastings, who sold 1,704. While company insiders often sell stock for various reasons, the timing of the sales ...NKTX | Oversold Healthcare Play | LONG Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific p Nkarta, Inc., a a clinical-stage biopharmaceutical ...

Nkarta Inc [NKTX] stock prices are up 6.02% to $2.64 at the moment. It is a good measure of the stock's recent performance to check whether the stock's short-term value is rising or falling. The NKTX shares have gain 1.93% over the last week, with a monthly amount glided 30.05%, and seem to be holding

Find real-time NXPI - NXP Semiconductors NV stock quotes, company profile, news and forecasts from CNN Business.

According to . 4 Wall Street analysts that have issued a 1 year NKTX price target, the average NKTX price target is $11.75, with the highest NKTX stock price forecast at $15.00 and the lowest NKTX stock price forecast at $9.00.If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.May 3, 2021 · NKTX : Nkarta stock forecast, predictions, and share price target for 2022, 2023 (1 year) to 2025 - 2027 (5 year) to 2030, and 2032 (10 year) with Revenue and EPS Prognosis by Technical Analysis The 12-month stock price forecast is $20.25, which is an increase of 208.69% from the latest price. Price Target. $20.25 (208.69% upside) Analyst Consensus: Strong Buy. Stock Forecasts. News. All; Videos; Press Press Releases; Conversation; ... Other symbols: AFMD BCAB EIGR GRCL NKTX TIL. 11 months ago - Barrons.According to the issued ratings of 7 analysts in the last year, the consensus rating for Vor Biopharma stock is Buy based on the current 7 buy ratings for VOR. The average twelve-month price prediction for Vor Biopharma is $15.19 with a high price target of $22.00 and a low price target of $10.00. Learn more on VOR's analyst rating history.ETNB Stock 12 Months Forecast. Based on 9 Wall Street analysts offering 12 month price targets for 89bio in the last 3 months. The average price target is $31.38 with a high forecast of $39.00 and a low forecast of $25.00. The average price target represents a 271.36% change from the last price of $8.45.At the end of Q3 2023, NKTX held $281.2 million in total current assets, $38.2 million of which was held in cash and equivalents, with another $237.4 in short-term investments.However, the unknown biotech stock holds value at current levels. With some promising developments, NKTX stock is likely to surge in 2023. For clinical-stage biotechnology companies, financing ...

Throughout the U.S., the weather can be quite unpredictable, even with state-of-the-art radar, sensors and computer modeling technology right at meteorologists’ fingertips. The Old Farmer’s Almanac first provided valuable statistics and dat...Find the latest Gritstone bio, Inc. (GRTS) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W ...Jun. 27, 2023, 10:25 AM. In a report released today, Gil Blum from Needham maintained a Buy rating on Nkarta ( NKTX – Research Report ), with a price target of $19.00. The company’s shares ...Instagram:https://instagram. what is the best wealth management firmhighest dividen stocksbest day trading stocks 2023best california dental insurance The average Barrick Gold stock price prediction forecasts a potential upside of 31.13% from the current GOLD share price of $17.73. What is GOLD's forecast return on ... what are + oddsadc stock dividend About the Nkarta, Inc. stock forecast. As of 2023 October 17, Tuesday current price of NKTX stock is 1.495$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).Nkarta (NKTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst William Maughan from Canaccord Genuity remains neutral on the stock and ... licycle stock Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Tempo Automation Holdings Inc have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 5.00.Apr 25, 2022 · All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange ... Reed's, Inc. (NYSE:REED) posted its quarterly earnings data on Thursday, November, 9th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.06. The business had revenue of $11.86 million for the quarter, compared to analysts' expectations of $15.38 million.